Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.53 |
| ▸ | GLP1R | P43220 | 6/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20398932 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2NOD1GLP1RFAAH | |
| SCHEMBL20398922 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2NOD1GLP1RFAAH | |
| SCHEMBL20398912 | 0.98 | SLC6A5 (0.61) | SLC6A5EPHX2NOD1GLP1RFAAH | |
| SCHEMBL20398914 | 0.98 | SLC6A5 (0.61) | SLC6A5EPHX2NOD1GLP1RFAAH | |
| SCHEMBL20398934 | 0.97 | SLC6A5 (0.62) | SLC6A5EPHX2NOD1FAAH | |
| SCHEMBL20398902 | 0.94 | SLC6A5 (0.55) | SLC6A5EPHX2NOD1GLP1R | |
| SCHEMBL20398903 | 0.94 | SLC6A5 (0.55) | SLC6A5EPHX2NOD1GLP1R | |
| SCHEMBL29187400 | 0.94 | NOD1 (0.60) | SLC6A5EPHX2NOD1GLP1R | |
| SCHEMBL25542921 | 0.94 | NOD1 (0.60) | SLC6A5EPHX2NOD1GLP1R | |
| SCHEMBL30667407 | 0.92 | SLC6A5 (0.58) | SLC6A5EPHX2NOD1GLP1RFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-11298326-B2 | Nucleic acid-containing lipid nanoparticles | KYOWA KIRIN CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-20180353434-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| WO-2018132876-A1 | NOVEL GLYCINE TRANSPORT INHIBITORS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF SYDNEY (AU) | 2018-07-26 | — | — | WO | disclosed |
| EP-3275448-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | SLC6A5 2256/4885EPHX2 1410/4885NOD1 3014/4885 |
| US-20180353434-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | FASN, ABHD16A, PHAX | SLC6A5 1565/4885EPHX2 2725/4885NOD1 1496/4885 |
| US-11298326-B2 | Nucleic acid-containing lipid nanoparticles | FASN, ABHD16A, PHAX | SLC6A5 1565/4885EPHX2 2725/4885NOD1 1496/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | SLC6A5 2256/4885EPHX2 1410/4885NOD1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.